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Results From the Nurses’ Health Study
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Objectives We assessed the association between depression and sudden cardiac death (SCD) and cardiac events among
individuals without baseline coronary heart disease (CHD).
Background Depression is a risk factor for cardiac events and mortality among those with CHD, possibly from arrhythmia.
Methods We studied depressive symptoms and a proxy variable for clinical depression consisting of severe symptoms
and/or antidepressant medication use and their relationship to cardiac events in the Nurses’ Health Study. Ques-
tionnaires in 1992, 1996, and 2000 assessed symptoms with the Mental Health Index (MHI-5), and antidepres-
sant use was assessed in 1996 and 2000. Primary end points included SCD, fatal CHD, and nonfatal myocardial
infarction.
Results Among 63,469 women without prior CHD/stroke in 1992, 7.9% had MHI-5 scores 53, previously found to pre-
dict clinical depression. Depressive symptoms were associated with CHD events, and the relationship was stron-
gest for fatal CHD, where the association remained significant even after controlling for CHD risk factors (hazard
ratio [HR]: 1.49; 95% confidence interval [CI]: 1.11 to 2.00 for MHI-5 score 53). In models from 1996 onward,
our proxy variable for clinical depression was most associated with SCD in multivariable models (HR: 2.33, 95%
CI: 1.47 to 3.70), and this risk was primarily due to a specific relationship between antidepressant use and SCD
(HR: 3.34, 95% CI: 2.03 to 5.50).
Conclusions In this cohort of women without baseline CHD, depressive symptoms were associated with fatal CHD, and a
measure of clinical depression including antidepressant use was specifically associated with SCD. Although anti-
depressant use might be a marker of worse depression, its specific association with SCD merits further
study. (J Am Coll Cardiol 2009;53:950–8) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.10.060A
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nepression has been identified as a possible risk factor for
n adverse prognosis and reduced survival after myocardial
nfarction (MI) (1), and several studies have suggested that
his poor prognosis might be due to an arrhythmic mecha-
ism (2–4). Abnormalities in heart rate variability, levels of
nflammatory biomarkers, platelet activation, omega-3 fatty
cid levels, and plasma norepinephrine have been identified
s potential mediators of this adverse prognosis (5–10).
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uman Development, and Health, Harvard School of Public Health, Boston,
assachusetts. This work was supported by grants CA-87969, HL-34594, and
L-03783 from the National Institutes of Healthl
Manuscript received June 16, 2008; revised manuscript received September 24,
008, accepted October 26, 2008.lthough depression seems to be a marker of increased risk
fter MI, it is currently unclear whether depression can be
onsidered an independent risk factor (11) or whether
reatment lowers this risk. The largest randomized trial thus
ar, the ENRICHD (Enhancing Recovery in Coronary
eart Disease Patients) trial, did not show improvement in
eath or recurrent MI among post-MI patients treated with
strategy of cognitive behavior therapy and selective sero-
onin reuptake inhibitors (SSRIs) (12).
See page 959
The relationship between depression and coronary heart
isease (CHD) incidence is even less certain, with fewer
bservational studies reporting positive associations (1) and
o randomized treatment trials. Also, there has been noarge prospective assessment of depression and sudden
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March 17, 2009:950–8 Depression and Cardiac Events Among Womenardiac death (SCD) risk among individuals without pre-
xisting CHD. The Nurses’ Health Study presented a unique
pportunity to analyze the prospective relationship between
epression and risk of SCD and other cardiac events, while
ontrolling for updated traditional and nontraditional
HD risk factors, in a large cohort of women without
aseline CHD.
ethods
he Nurses’ Health Study cohort. The Nurses’ Health
tudy began in 1976 when 121,701 female registered
urses, ages 30 to 55 years, completed a questionnaire about
heir medical history, CHD risk factors, and lifestyle fac-
ors. The cohort has been followed every 2 years with mailed
uestionnaires that update exposure information and in-
uire about newly diagnosed medical illnesses. Deaths are
eported by next-of-kin or postal authorities or identified
hrough the National Death Index. Family members are
sked for permission to obtain further information from
edical records and are interviewed about the circumstances
urrounding the death if not adequately documented in the
edical record. Subjects or family members provided writ-
en informed consent, and the study was approved by the
nstitutional review board of Partners HealthCare System,
oston, Massachusetts. For this analysis, we excluded par-
icipants with a prior history of CHD, stroke, or cancer at
aseline.
epression measure. Self-reported symptoms of depres-
ion and use of antidepressant medication were used as
easures of depression. Depressive symptoms were assessed
n 1992, 1996, and 2000 with the Mental Health Index
MHI-5), a 5-item subscale of the Short-Form 36 health
tatus survey (13,14) designed to capture psychological
istress versus well-being (15,16). The MHI-5 asks respon-
ents how much of the time over the past month (all, most,
ood bit, some, little, or none) they felt nervous, felt so
own that nothing could cheer them up, felt calm and
eaceful, felt down and blue, or felt happy. The scale is
cored from 0 to 100, with lower scores indicating more
epressive symptoms. The MHI-5 has been shown to have
igh sensitivity and specificity for major depression, with an
rea under the receiver-operating characteristic curve of 0.88
o 0.91 for the detection of mood disorders or major
epression. In accordance with a prior study using this scale
17), we divided the participants into 4 categories of
epressive symptoms according to their MHI-5 score (77 to
00, 76 to 85, 53 to 75, 0 to 52).
For our clinical depression analyses, we created a proxy
easure for clinical depression consisting of a low MHI-5
core or reported regular antidepressant medication use.
articipants were first asked to report regular antidepressant
edication use in 1996, the baseline year for these analyses.
his information was updated in 2000, when participants
ere asked to specifically report their regular use during the aast 2 years of fluoxetine, sertra-
ine, paroxetine, citalopram, or
ther antidepressants, of which
he tricyclic antidepressants ami-
riptyline, imipramine, and nor-
riptyline were provided as exam-
les. Because an MHI-5 score of
2 or lower has been found to be
redictive of major depression
18), this cutoff was used to de-
ne the group with “clinically
ignificant depressive symptoms”
nd was combined with antide-
ressant use for the clinical de-
ression analyses. Our proxy
ariable was found to highly cor-
elate with a report of being previously diagnosed with
linical depression on the 2000 questionnaire (correlation
oefficient 0.49, p  0.001).
nd point definition. The study end points included
ncident cases of SCD, fatal CHD, and nonfatal MI that
ccurred after return of the 1992 questionnaire and before
une 1, 2004. The specific details regarding the classification
f SCD in this cohort are described in detail elsewhere (19).
riefly, a cardiac death was considered sudden if the death
r cardiac arrest that precipitated death occurred within 1 h
f symptom onset as documented by medical records or
ext-of-kin reports. Unwitnessed deaths that could have
ccurred within 1 h of symptom onset with autopsy findings
onsistent with SCD were considered probable SCDs and
ere also included in the analysis. Secondary analyses were
erformed with SCD or death during sleep in the absence of
rior known symptoms.
Fatal CHD was defined as International Classification of
iseases-9 codes 410 to 412 if confirmed by hospital records
r autopsy or if CHD was the most likely cause and was
isted as the cause of death on the death certificate, along
ith evidence of prior CHD. We designated as probable
HD those cases in which CHD was the underlying cause
n the death certificate but for which no medical records
oncerning the death were available and included these cases
n the analysis.
All women who reported having a nonfatal MI were
sked for permission to review their medical records. The
Is were confirmed according to World Health Organiza-
ion criteria by physicians blinded to exposure status. The
Is that required hospital admission and for which confir-
atory information was obtained by interview or letter but
or which no medical records were available were designated
s probable and included in the analysis.
tatistical analyses. We computed age-adjusted means or
roportions of cardiovascular risk factors across categories of
HI-5 score reported in 1992. Baseline measurements of
ardiac risk factors were compared across MHI-5 category
ith Mantel-Haenszel chi-square tests for categorical vari-
Abbreviations
and Acronyms
CABG  coronary artery
bypass graft
CHD  coronary heart
disease
CI  confidence interval
HR  hazard ratio
MHI  Mental Health Index
MI  myocardial infarction
SCD  sudden cardiac
death
SSRI  selective serotonin
reuptake inhibitorbles and linear regression for continuous variables.
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Depression and Cardiac Events Among Women March 17, 2009:950–8For the depressive symptom analysis, women who re-
ponded to the MHI-5 items on any of the 1992, 1996, or
000 questionnaires were included in the analysis from the
ime of their earliest questionnaire response. Participants
ith a prior history of CHD, stroke, or cancer in the
aseline year were excluded from both analyses. For each
oman we calculated person-months of follow-up from the
ate of return of the earliest questionnaire to date of first
nd point, death, or to June 1, 2004, whichever came first.
e used Cox proportional hazards models to estimate age-
nd multivariable-adjusted hazard ratios (HRs). The
HI-5 score was treated as a time-dependent variable
sing the most recent exposure to predict outcome, and the
ast observation was carried forward for those with missing
alues at a particular time point. Tests for linear trend were
erformed by including MHI-5 score as a continuous
ariable in separate proportional hazards models.
Two multivariable models were performed; the first
odel (multivariable model I) simultaneously adjusted for
pdated coronary risk factors except for reported nonfatal
HD during follow-up, hypertension, and diabetes, 3
ossible biologic intermediates in the relationship between
epression and heart disease outcome. The first model
ncluded variables for age, beginning year of follow-up,
moking status (never, past, current 1 to 14, 15 to 24, 25
igarettes/day), body mass index (25, 25 to 29.9, 30
g/m2), alcohol intake (0, 5, 5 to 14, 15 g/day),
enopausal status and postmenopausal hormone use, usual
spirin use (1, 1 to 6, and 7/week), multivitamin use,
itamin E supplement use, hypercholesterolemia, family
istory of MI (no, before age 60 years, after age 60 years),
istory of stroke, n-3 fatty acid intake (quintiles), alpha
inolenic acid intake (quintiles), and moderate/vigorous
hysical activity (0, 1 to 1.9, 2 to 3.9, 4 h/week). The
econd multivariable model (multivariable model II) included
he variables in model I, with the addition of nonfatal CHD
uring follow-up, hypertension, and diabetes.
For the clinical depression analysis, unadjusted Kaplan-
eier curves of time to cardiac event were estimated with
996 baseline measurements of our proxy variable for
linical depression. Cox proportional hazards analyses in-
luded women who responded to the MHI-5 items and
ntidepressant medication questions on the 1996 or 2000
uestionnaire, from the time of their earliest questionnaire
esponse. Depression exposure was treated as a time-
ependent variable, and multivariable models I and II
ncluded the same updated time-dependent covariates as
escribed in the preceding text. All reported p values are
-sided. Statistical analysis was performed with SAS statis-
ical software version 8.2 (SAS Institute Inc., Cary, North
arolina).
ensitivity analyses. To evaluate the possibility of reverse
ausality associated with the development of nonfatal CHD,
e performed analyses excluding individuals who reported
eing diagnosed with another nonfatal CHD (angina,
oronary artery bypass graft [CABG], or MI) end pointefore the study outcome in question. We also evaluated for
n interaction between MHI-5 score and prior diagnosis of
HD in the entire population, through the inclusion of
ross-product terms in our proportional hazards models. In
ddition, we performed sensitivity analyses of our results for
onfatal MI by excluding cases not confirmed by medical
ecord review.
esults
epressive symptoms. In 1992, 63,469 women of 102,482
61.9%) total participants without prior CHD, stroke, or
ancer responded to the items of the MHI-5. The median
HI-5 score was 80 (IQR 68 to 88), and 4,994 women
7.9% of the total) had an MHI-5 score 53, which has
een shown to be predictive of clinical depression (Fig. 1)
18). Compared with women with an MHI-5 score 86 to
00, women with worse symptoms of depression—as rep-
esented by lower MHI-5 score—were younger and more
ikely to report a history of hypertension, diabetes, and high
holesterol (Table 1). Women with more depressive symp-
oms were also more likely to be smokers, obese, and less
hysically active. The n-3 fatty acid intake was lower among
articipants with worse symptoms of depression, and regular
spirin and multivitamin use was higher.
Table 2 displays the association between depressive
ymptoms, as measured by the MHI-5 score, and risk of
CD, fatal CHD, and nonfatal MI. Hazard ratios are
hown for each MHI-5 category, compared with the
eference category (MHI-5 score 86 to 100). In age-
djusted proportional hazards analyses, a lower MHI-5
core (i.e., more severe depressive symptoms) was asso-
iated with an increased risk of all 3 CHD outcomes.
owever, these associations were attenuated in multiva-
iable analyses that included CHD risk factors, except for
ossible biological mediators (multivariable model I), and
elationships for SCD and nonfatal MI became nonsig-
ificant in the fully adjusted model (multivariable model
I). The relationship between MHI-5 score and CHD
ortality was attenuated but remained statistically sig-
Figure 1
Distribution of MHI-5 Score Among
63,469 Women Without Prior Coronary
Heart Disease, Stroke, or Cancer in 1992
MHI  Mental Health Index.
n
t
r
w
p
t
S
m
9
r
t
r
(
H
a
(
n
d
e
d
t
c
m
a
C
4
M
a
2
a
t
S
3

w
2
r
a
d
u
a
CS
V
953JACC Vol. 53, No. 11, 2009 Whang et al.
March 17, 2009:950–8 Depression and Cardiac Events Among Womenificant (HR: 1.49 for MHI-5 score 53; 95% CI: 1.11
o 2.00; p trend  0.007) in the fully adjusted multiva-
iable model. When deaths that occurred during sleep
ithout prior symptoms were included in the SCD end
oint (number of end points increased from 138 to 176),
he association between symptoms of depression and
CD also remained significant but attenuated in the full
ultivariable model (HR: 1.51 for MHI-5 score 53;
5% CI: 0.89 to 2.56; p trend  0.01).
To evaluate the sensitivity of these results to possible
everse causality associated with the development of nonfa-
al CHD, we performed analyses excluding all women who
eported being diagnosed with another nonfatal CHD event
angina, CABG, or MI) before each study outcome. The
R for each MHI-5 score category (data not shown) as well
s the overall association between depression score and SCD
p for trend 0.079), fatal CHD (p for trend 0.008), and
onfatal MI (p for trend  0.28) were not materially
ifferent from our primary analyses. There was also no
vidence for an interaction between MHI-5 score and CHD
uring follow-up for any of the CHD outcomes. In addi-
HD Risk Factors Among 63,469 Women Without Prior CHD,troke, or Cancer According to Depressio Symptom Category in 1
Table 1 CHD Risk Factors
 Among 63,469 Women Without Pri
Stroke, or Cancer According to Depression Symptom C
86–100 (Referent)
No. of women (% total) 18,631 (29.4)
Mean age, yrs (SD)* 59.6 (7.1)
Smoking*
Past 7,453 (39.9)
Current 1–14 cigarettes/day 952 (5.1)
Current 15–24 cigarettes/day 865 (4.8)
Current 25 cigarettes/day 366 (2.0)
Reported diagnosis of
Diabetes* 809 (4.1)
High cholesterol* 7,692 (39.7)
Hypertension* 5,562 (28.3)
Body mass index 30 kg/m2* 3,001 (16.2)
Parental history of MI before age 60 yrs 2,399 (13.1)
Alcohol intake, g/day*
0.1–4.9 5,357 (29.0)
5.0–14.9 3,018 (16.1)
15.0 1,510 (7.9)
Aspirin use, 7/week* 2,177 (11.5)
Post-menopausal* 14,945 (75.6)
n-3 fatty acid intake as % total calories (SD)* 0.145 (0.152)
Alpha linolenic acid intake as % total calories (SD) 0.530 (0.152)
Vitamin supplement use
Vitamin E 3,262 (17.2)
Multivitamin* 7,661 (40.7)
Moderate/vigorous physical activity, h/week*
0–1.9 5,637 (30.3)
2–3.9 3,236 (17.6)
4 4,109 (22.1)
alues are n (%) unless otherwise indicated. Age-adjusted. *p  0.01.
CHD  coronary heart disease; MI  myocardial infarction.ion, for analyses of nonfatal MI, exclusion of cases not oonfirmed by medical record review (24.6% of cases) did not
aterially change the results compared with our primary
nalyses.
linical depression and antidepressant use. In 1996,
,280 women (6.0% of the cohort in that year) had an
HI-5 score 53, and in 2000, 3,399 women (4.8%) had
n MHI-5 score 53. In 1996, 4,769 women (6.7%) and in
000, 6,869 women (9.7%) reported use of medications that
re commonly used as antidepressants. In 2000, among
hose reporting antidepressant use, 61% reported using an
SRI (sertraline, fluoxetine, paroxetine, or citalopram), and
9% reported “other antidepressant use.” An MHI-5 score
53 and antidepressant use both significantly correlated
ith a report of a diagnosis of clinical depression on the
000 questionnaire (correlation coefficient 0.21 and 0.54,
espectively).
Using this information on antidepressant use, we evalu-
ted the association between a proxy variable for clinical
epression, which consisted of either MHI-5 score 53 or
se of antidepressant medication, and cardiac events. Un-
djusted Kaplan-Meier curves with 1996 baseline data for
D,
ory in 1992
Depression Symptom Score
76–85 53–75 0–52 (Depressive)
22,814 (36.0) 17,030 (26.8) 4,994 (7.9)
58.3 (7.2) 57.6 (7.2) 56.7 (7.4)
9,521 (41.7) 7,199 (42.5) 2,068 (41.8)
1,305 (5.7) 1,120 (6.6) 320 (6.4)
1,187 (5.2) 1,167 (6.8) 384 (7.4)
478 (2.1) 503 (2.9) 241 (4.8)
973 (4.3) 865 (5.3) 294 (6.3)
9,951 (43.7) 7,813 (46.9) 2,417 (50.4)
7,165 (31.5) 5,768 (34.9) 1,774 (38.0)
3,773 (16.5) 2,968 (17.3) 1,038 (20.7)
3,007 (13.2) 2,282 (13.3) 686 (13.2)
6,592 (28.9) 4,946 (28.9) 1,347 (26.6)
3,793 (16.6) 2,705 (15.9) 682 (13.6)
1,874 (8.2) 1,314 (7.8) 386 (7.8)
2,797 (12.3) 2,505 (14.8) 859 (17.2)
17,177 (75.5) 12,347 (75.5) 3,467 (76.0)
0.143 (0.143) 0.139 (0.133) 0.136 (0.146)
0.527 (0.149) 0.526 (0.150) 0.528 (0.156)
3,939 (17.3) 2,981 (17.8) 868 (17.8)
9,759 (42.8) 7,421 (43.8) 2,206 (44.7)
7,493 (32.8) 5,840 (34.2) 1,699 (33.9)
4,011 (17.6) 2,640 (15.4) 671 (13.1)
4,352 (19.1) 2,663 (15.6) 612 (12.1)992
or CH
ategur proxy measure are shown in Figure 2, and multivariable
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Depression and Cardiac Events Among Women March 17, 2009:950–8roportional hazards analyses using time-varying measure-
ents are shown in Table 3. The proxy variable for clinical
epression was associated with increased risk of all 3 CHD
utcomes in age-adjusted and multivariable models exclud-
ng biological intermediates, similar to the results for
HI-5 score. However, the elevation in risk was greatest
or SCD, where a 2.33-fold association (95% CI: 1.47 to
.70, p  0.001) persisted in the full multivariable model
multivariable model II). In comparison, the associations for
atal CHD (HR: 1.37, 95% CI: 1.04 to 1.81; p  0.03) and
onfatal MI (HR: 1.20, 95% CI: 0.99 to 1.46; p  0.06)
ere markedly attenuated and only marginally significant
fter full multivariable adjustment. Similar to the results
or depressive symptoms, these results for the proxy
easure of clinical depression were not materially altered
hen women who developed an intervening nonfatal
HD event (angina, CABG, or MI) were excluded from
he analysis (for SCD, HR: 2.20, 95% CI: 1.35 to 3.57,
 0.002; for fatal CHD, HR: 1.31, 95% CI: 0.96 to
.78, p  0.09; for nonfatal MI, HR: 1.25, 95% CI: 1.03
o 1.53, p  0.027).
To further evaluate the elevated risk of SCD associated
ith the composite clinical depression measure, we assessed
he individual components (MHI-5 score 53 and antide-
ressant use) simultaneously in proportional hazard models
Table 4). In these models, antidepressant medication use
as associated with a markedly elevated risk of SCD in the
ully adjusted models (HR: 3.34, 95% CI: 2.03 to 5.50),
hereas MHI-5 score 53 no longer conferred an elevated
isk (HR: 1.04, 95% CI: 0.51 to 2.12). By contrast, there
as no relationship between antidepressant use and fatal
ong-Term Relative Risks (95% CI) of Mortality/MI Among 81,875ithout Prior CHD, Stroke, or Cancer at Baseline Followed From 1
Table 2 Long-Term Relative Risks (95% CI) of Mortality/MI AmWithout Prior CHD, Stroke, or Cancer at Baseline Follo
Outcome
Depression Sym
86–100 (Referent) 76–85
Person-yrs 311,391 293,969
SCD
No. of cases 46 37
Age-adjusted 1.0 0.98 (0.64–1.51)
Multivariable I 1.0 0.91 (0.59–1.41)
Multivariable II 1.0 0.87 (0.56–1.34)
Fatal CHD
No. of cases 171 147
Age-adjusted 1.0 1.01 (0.81–1.25)
Multivariable I 1.0 0.93 (0.74–1.15)
Multivariable II 1.0 0.86 (0.69–1.07)
MI
No. of cases 406 392
Age-adjusted 1.0 1.10 (0.95–1.26)
Multivariable I 1.0 1.05 (0.92–1.21)
Multivariable II 1.0 1.03 (0.89–1.18)
ccording to categories of depression symptom score. Hazard ratios from proportional hazards mo
ny of the 1992, 1996, or 2000 questionnaires and were free of prior coronary heart disease, stro
ime point on. Please see Methods section for description of variables for multivariable models I
CI  confidence interval; SCD  sudden cardiac death; other abbreviations as in Table 1.HD (HR: 1.07, 95% CI: 0.75 to 1.53) or nonfatal MI tHR: 1.21, 95% CI: 0.96 to 1.53) in these models. Unad-
usted Kaplan-Meier curves of time to SCD stratified by
ntidepressant use and MHI-5 score 53 at baseline in
996 are shown in Figure 3. In a secondary analysis of data
rom 2000 to 2004 with separate variables for SSRI use and
other antidepressant use” (31 total SCDs), we found
imilar HRs for the 2 categories of medications in age-
djusted analyses (for SSRI use, HR: 5.07, 95% CI: 1.73 to
4.8; for other antidepressant use, HR: 3.19, 95% CI: 0.92
o 11.00).
iscussion
n this prospective study among women without known
ardiovascular disease at baseline, symptoms of depression
ere directly associated with the risk of CHD events in
ge-adjusted and multivariable models excluding potential
iologic intermediates. Symptoms were most strongly re-
ated to fatal CHD events, where the association remained
ignificant even after controlling for all CHD risk factors.
owever, depressive symptoms were also associated with
ultiple risk factors for CHD, and the relationships be-
ween depressive symptoms and all 3 end points, including
atal CHD, were attenuated in multivariable analyses that
djusted for updated CHD risk factor status. These CHD
isk factors might act as biologic intermediates in the
elationship between depressive symptoms and cardiac
vents, given their strong association with depression in this
nd prior studies (20). When we examined a proxy variable
or clinical depression that consisted of either MHI-5 score
53 or use of antidepressant medication, a strong associa-
eno 2004
81,875 Women
From 1992 to 2004
Score
p for Trend* (Continuous)53–75 0–52 (Depressive)
201,794 54,932
43 12
2 (1.13–2.61) 1.96 (1.03–3.71) 0.001
6 (0.89–2.08) 1.36 (0.71–2.61) 0.050
7 (0.83–1.94) 1.21 (0.63–2.33) 0.13
159 64
7 (1.35–2.08) 2.81 (2.11–3.75) 0.001
0 (1.04–1.62) 1.79 (1.33–2.40) 0.001
4 (0.91–1.42) 1.49 (1.11–2.00) 0.007
298 87
7 (1.09–1.47) 1.49 (1.18–1.87) 0.001
4 (0.98–1.33) 1.24 (0.98–1.57) 0.02
8 (0.93–1.25) 1.13 (0.90–1.43) 0.19
th time-dependent variables. Women who responded to the Mental Health Index (MHI-5) items on
ancer at the time of their earliest questionnaire response were included in the analysis from this
The p value reflects test for linear trend with MHI-5 score as continuous variable.Wom992 t
ong
wed
ptom
1.7
1.3
1.2
1.6
1.3
1.1
1.2
1.1
1.0
dels wi
ke, or cion with risk of SCD emerged that was not attenuated in
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March 17, 2009:950–8 Depression and Cardiac Events Among Womenultivariable models. When examined separately, this in-
reased risk seemed to result primarily from a specific
levation in the risk of SCD among women who reported
ntidepressant use. Neither depression score nor antidepres-
ant use was significantly associated with nonfatal events in
ultivariable models.
Prior studies have examined the association between
epression and incident cardiac events, with varying results.
wo meta-analyses of observational studies both estimated
hat depression conferred a 1.6-fold increased risk of CHD
21,22) and clinically relevant depression seemed to be a
tronger predictor than depressive symptoms (22)—similar
Figure 2 Unadjusted Kaplan-Meier
Curves of Time to First Event
Unadjusted Kaplan-Meier curves of time to first event for sudden cardiac death
(A), fatal coronary heart disease (B), and nonfatal myocardial infarction (C),
according to depression status as defined by Mental Health Index-5 score 53
or reported use of antidepressant medication at baseline starting in 1996.
Curves are truncated at 42 months. The p values for log-rank test were 0.02
for sudden cardiac death, 0.31 for fatal coronary heart disease, and 0.80 for
nonfatal myocardial infarction.o the relationship observed here for SCD. With respect to
srior large-scale data among women, investigators from the
omen’s Health Initiative also found that depressive
ymptoms were associated with a significantly higher risk of
atal cardiovascular events (adjusted risk ratio: 1.5, 95% CI:
.10 to 2.03) among 73,098 women without a history of
ardiovascular disease over 4 years of follow-up (23). As
bserved in our study, relationships seemed stronger for
atal versus nonfatal events; however, separate risks were not
eported for antidepressant use, and SCD was not specifi-
ally examined.
Part of the association with fatal events observed in this
nd previous studies could be explained if part of the
levated mortality risk associated with depression were due
o an increased risk of fatal ventricular arrhythmias. The
trong association between our proxy measure of clinical
epression and SCD supports this possibility. A large case
ontrol study also found a significant association between a
iagnosis of clinical depression and out-of-hospital cardiac
rrest independent of established CHD risk factors (2).
epressive symptoms have also been specifically associated
ith ventricular arrhythmias among individuals with im-
lantable defibrillators (3). Possible mechanisms for the
levated risk of ventricular arrhythmias and SCD associated
ith depression include greater sympathetic nervous system
ctivation (9), higher resting heart rates, increases in QT
ispersion (24), and reduced heart rate variability (8) among
ndividuals with depression. Another possibility is that
reatments for depression might elevate the risk of ventric-
lar arrhythmias. When examined separately, we found an
levated risk of SCD associated with antidepressant use and
ot with more severe depressive symptoms according to
HI-5 score 53. It is also noteworthy that, as opposed to
he HR corresponding to MHI-5 score, the HR for SCD
orresponding to antidepressant use was minimally attenu-
ted despite adjustment for multiple coronary risk factors
HR in fully adjusted model: 3.34, 95% CI: 2.03 to 5.50).
Rs (95% CI) for Mortality/MI Among 75,718omen Without Pri CHD, Stroke, or Cancerollowed a Baseline 1996 to 2004
Table 3
HRs (95% CI) for Mortality/MI Among 75,718
Women Without Prior CHD, Stroke, or Cancer
Followed at Baseline 1996 to 2004
Outcome HR (95% CI) p Value
SCD (n  99)
Age-adjusted 2.91 (1.85–4.57) 0.001
Multivariable I 2.49 (1.57–3.94) 0.001
Multivariable II 2.33 (1.47–3.70) 0.001
Fatal CHD (n  342)
Age-adjusted 1.87 (1.42–2.46) 0.001
Multivariable I 1.54 (1.17–2.03) 0.002
Multivariable II 1.37 (1.04–1.81) 0.03
MI (n  811)
Age-adjusted 1.41 (1.17–1.71) 0.001
Multivariable I 1.28 (1.05–1.56) 0.01
Multivariable II 1.20 (0.99–1.46) 0.06
ccording to depression score53 or use of antidepressant medication (in 1996 or 2000). Please
ee Methods section for description of variables for multivariable models I and II.
HR  hazard ratio; other abbreviations as in Tables 1 and 2.
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Depression and Cardiac Events Among Women March 17, 2009:950–8In addition to our own study, prior observational studies
ave noted a higher mortality risk associated with antide-
ressant use in patients with heart failure (25) and in
atients undergoing CABG surgery (26). Fluoxetine, which
as been shown to cause direct and indirect reductions in
he human ether-a-go-go-related gene potassium current in
human embryonic kidney cell model (27), has been
eported to result in QT prolongation and torsades de
ointes (28,29). Tricyclic antidepressants are also known to
ause QT prolongation and ventricular arrhythmias in
Figure 3 Unadjusted Kaplan-Meier Curves
of Time to Sudden Cardiac Death
Unadjusted Kaplan-Meier curves of time to sudden cardiac death stratified by
Mental Health Index-5 score 53 and reported use of antidepressant medica-
tion at baseline starting in 1996. The p value for log-rank test across strata
was 0.01.
HRs (95% CI) for Mortality/MI Among 75,718 WWithout Prior CHD, Stroke, or Cancer Followed
Table 4 HRs (95% CI) for Mortality/MI AmoWithout Prior CHD, Stroke, or Canc
Outcome
Depression Score
HR (95% CI)
SCD (n  99)
Age-adjusted 1.36 (0.67–2.77)
Multivariable I 1.09 (0.53–2.24)
Multivariable II 1.04 (0.51–2.12)
Fatal CHD (n  342)
Age-adjusted 2.07 (1.43–2.99)
Multivariable I 1.58 (1.09–2.29)
Multivariable II 1.41 (0.97–2.04)
MI (n  814)
Age-adjusted 1.14 (0.85–1.54)
Multivariable I 1.05 (0.78–1.41)
Multivariable II 0.98 (0.73–1.33)
From multivariable models that included depression score 53 and
section for description of variables for multivariable models I and II.
HR  hazard ratio; other abbreviations as in Tables 1 and 2.Qverdose and, in doses 100 mg, have been associated with
CD risk in a retrospective cohort study (30). In this same
tudy, standard doses of SSRIs and tricyclic antidepressants
ere not associated with increased risk; however, the study
as unable to control for other confounding factors.
Although proarrhythmic effects from antidepressant medi-
ations might have resulted in a higher risk of SCD in our
tudy, it must be emphasized that observational studies cannot
rove causality, and confounding by indication can never be
ompletely ruled out. Because antidepressant use more signif-
cantly correlated with a diagnosis of clinical depression than
he MHI-5 score, it is entirely possible that antidepressant use
dentified participants with more severe depression that was
ot fully captured by the MHI-5 questionnaire. In addition,
hese risks need to be put in perspective and balanced against
nown benefits of these medications on depression. Sudden
ardiac death among healthy women is an uncommon event,
nd although elevated, the absolute risk among women who
eported antidepressant use in this study was still very low (46
CDs/100,000 person-years).
Although the individual risk is low, the possible public
ealth implications of an arrhythmic risk from these com-
only prescribed medications at a societal level remain
arge. This potential risk coupled with recent data suggest-
ng that the clinical benefit of newer antidepressant agents
ight be less than previously thought (31) highlights the
eed for large-scale randomized trials of antidepressant
edications that are adequately designed and powered to
etect important adverse cardiovascular outcomes such as
roarrhythmia as well as efficacy. Although the SADHART
Sertraline Antidepressant Heart Attack Randomized Trial)
rial was specifically designed to examine cardiovascular
afety in patients with acute MI or unstable angina, the
rimary study end points were intermediate end points such
s left ventricular ejection fraction and significant corrected
n1996 to 2004
5,718 Women
llowed From 1996 to 2004
Antidepressant Medication Use
Value HR (95% CI) p Value
0.40 3.59 (2.20–5.86) 0.001
0.81 3.53 (2.15–5.81) 0.001
0.92 3.34 (2.03–5.50) 0.001
0.001 1.30 (0.91–1.84) 0.15
0.02 1.19 (0.83–1.70) 0.34
0.07 1.07 (0.75–1.53) 0.71
0.38 1.38 (1.10–1.74) 0.006
0.77 1.27 (1.01–1.60) 0.04
0.91 1.21 (0.96–1.53) 0.10
antidepressant medication (in 1996 or 2000). Please see MethodsomeFrom
ng 7
er Fo
<53
p
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use ofT interval prolongation (32). With only 369 patients
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March 17, 2009:950–8 Depression and Cardiac Events Among Womennrolled, the trial had minimal power to examine hard end
oints such as SCD or fatal CHD. The largest randomized
rial thus far, the ENRICHD trial, enrolled 2,481 post-MI
atients and did not find an increase or decrease in the risk of
eath or recurrent MI associated with cognitive behavioral
herapy supplemented with SSRI but raised the possibility of
n interaction by sex, with higher risks of cardiovascular events
mong women treated with the intervention (12).
Strengths of our study include the relatively large sample
ize, the long follow-up period, rigorously documented
HD end points, and the updated measures of depression
nd cardiac risk factors over the course of follow-up. There
re also additional limitations of the present study that
arrant consideration. First, reverse causality might account
or at least part of the association observed between depres-
ion and cardiovascular disease in this and other observa-
ional studies. Individuals who are diagnosed with CHD or
ith conditions that predispose them to coronary disease
uch as diabetes or hypertension might develop depression
nd therefore would also be at higher risk for fatal cardiac
vents. Our study excluded women with known CHD at
aseline, and sensitivity analyses that excluded participants
ho reported CHD in follow-up did not significantly
hange our results, arguing that reverse causality by symp-
omatic CHD is less likely to be a significant source of bias.
lthough we attempted to adjust for as many potential
onfounding factors as possible in our multivariable analy-
es, there might still be residual confounding from CHD
isk factors and prevalent CHD. Also, for the nonfatal MI
nalysis: women who are depressed might be more likely to
elf-report MI, and this could inflate the detection of MI,
articularly with respect to the probable cases not confirmed
y medical records. However, analyses excluding these
robable cases revealed similar results.
Second, we did not have a measure of adherence to
edications in our data. Because depression has previously
een associated with reduced adherence to medications (33),
dherence might be a confounder in our results. Also, we
id not collect information on antidepressant dose, and
herefore, it is not possible to analyze our data for a
ose-response relationship between antidepressants and
CD. In addition, our analysis does not include other
omorbid psychologic factors, such as anxiety, which might
e collinear with depression and which has been correlated
ith arrhythmia (34). Another limitation is the relatively
mall number of SCD events in our analyses (138 SCDs for
nalyses starting in 1992, 99 SCDs for analyses starting in
996), compared with the fatal CHD and nonfatal MI end
oints. Finally, the Nurses’ Health Study represents a
elatively healthy group of mostly Caucasian females, and
ndings from this analysis might not be generalizable to
ther populations. However, the estimated 7.9% preva-
ence of depression as measured by an MHI-5 score 53
s comparable to the prevalence of major depression
4.8%) estimated among white women ages 45 to 54 yearsith a structured interview in the National Comorbidity
urvey (35).
onclusions
n this prospective cohort of women without baseline
ardiovascular disease, we found that symptoms of depres-
ion are associated with higher risks of cardiac events, and at
east part of this association seems to be explained by
ifferences in coronary risk factors, which might act as
ausal intermediates in the risk conferred by depression.
hen we used a proxy for clinical depression, which
ncluded antidepressant medication use, we observed a
tronger association for SCD, suggesting a possible
roarrhythmic mechanism. Although antidepressant
edication use might be a marker of worse depression, its
pecific association with elevated risk of SCD merits
urther study.
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